公开(公告)号：EP2359828A1

公开(公告)日：2011-08-24

申请号：EP11154644.6

申请日：2008-06-06

申请人： University of Maryland, Baltimore

发明人： Brodie, Angela ,  Njar, Vincent ,  Sabnis, Gauri ,  Gediya, Lalji

IPC分类号： A61K31/495 ,  A61K31/44 ,  C07D233/54 ,  C07C259/10 ,  C07D215/20 ,  A61K31/10 ,  A61K31/196 ,  A61K31/4196

CPC分类号： A61K31/44 ,  A61K31/10 ,  A61K31/196 ,  A61K31/4196 ,  A61K31/495 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase inhibitor, which is MS-275 and a hormone targeted drug to an individual with cancer. In specific embodiments, the histone deacetylase inhibitor and the hormone targeted drug act synergistically to treat the cancer, including by overcoming resistance to a cancer therapy.

摘要翻译： 本发明涉及例如治疗内分泌调节癌症的方法，包括激素抵抗性癌症。 更具体地，本发明涉及增加激素抗性癌症对激素治疗剂的敏感性的方法。 在具体实施方案中，本发明涉及组氨酸脱乙酰酶抑制剂，其是具有癌症的个体的MS-275和激素靶向药物。 在具体实施方案中，组蛋白脱乙酰酶抑制剂和激素靶向药物协同作用以治疗癌症，包括克服对癌症治疗的抗性。